BMY · Bristol-Myers Squibb Company

S&P 500 #102 · NYSE

Risiko 4/10 · Stable Dividend Value · $63.60 ▲ 1.66%

Kennzahlen

• Price $63.60
• Market cap $129.9B
• P/E (ttm) 17.82
• Div yield 4.03%
• 52-wk range $42.52 – $64.97
• Index rank #102 / —

Wichtigste Risiken

• Patent cliff (Eliquis/Revlimid) (Shareholders) — HIGH
• Pipeline execution risk (Long-term investors) — MED
• Drug pricing/IRA headwinds (All holders) — MED
• Debt load from Celgene acquisition (Credit investors) — LOW

Fazit

Large-cap pharma rebuilding its pipeline post-Eliquis patent cliff while leaning on a generous 4.4% dividend yield.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.